Company news

Alterity Therapeutics Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting

April 10, 2025

Alterity Phase 2 Presentation at AAN 2025

April 10, 2025

Alterity Presents Encouraging New Phase 2 Data in MSA

April 10, 2025

Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting

April 9, 2025

Alterity Therapeutics to Deliver an Oral Presentation of the Positive ATH434 Phase 2 Trial Results at the American Academy of Neurology Annual Meeting

April 3, 2025

Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy

March 27, 2025

Alterity Completes Last Patient Visit in Open-Label Trial

March 27, 2025

Alterity raises A$40m to Advance ATH434 Development in MSA

February 9, 2025

Alterity Raises Funds for ATH434 BD and Clinical Activities

February 2, 2025

Positive ATH434 Phase 2 Results Led By Clinical Efficacy

January 29, 2025

Alterity Announces Completion of Phase 2 Clinical Trial

December 3, 2024

Appendix 4E Preliminary Final Report

August 29, 2024

Positive Interim Data from ATH434-202 Phase 2 Clinical Trial

July 17, 2024

Alterity Receives a $3.9 million R&D Tax Incentive Refund

March 26, 2024

Alterity Therapeutics Raises $3.25 M AUD in Placement

February 22, 2024

Phase 2 DMC Recommends Continuing Clinical Trial as Planned

February 6, 2024

Positive Efficacy Data for ATH434 in a Primate Model of PD

December 3, 2023

Alterity Therapeutics Raises $4.8M AUD in Placement

November 21, 2023

ATH completes enrolment in ATH434-201 Phase 2 clinical trial

November 7, 2023

Appendix 4E and Annual Report 2023

August 31, 2023

Alterity Presents New Data on Multiple System Atrophy

August 31, 2023

Alterity Granted New Composition of Matter Patent in Europe

August 23, 2023

Alterity receives a $4.74 million R&D Tax Refund

August 15, 2023

Ph 2 Data Monitoring Committee Recommends Continuing Trial

July 26, 2023

Investor Presentation

June 22, 2023

ATH starts 2nd Phase 2 Study in Rare Parkinsonian Disorder

May 30, 2023

Appendix 4C and Quarterly Cash Flow Report

April 27, 2023

US patent grant and license agreement

March 14, 2023

First Patient Enrolled in Europe in Phase II Clinical trial

March 7, 2023

Regulatory approval for Phase II trial in France and Austria

February 16, 2023

ATH434 Clinical Trial Launched in Italy

January 24, 2023

ATH434 clinical trial launched in the US

January 9, 2023

New US patent for compounds to treat neurodegeneration

December 29, 2022

ATH434 Clinical Trial launched in Australia

October 13, 2022

US FDA Approval for IND Application for ATH434 for MSA

September 19, 2022

Appendix 4E & Annual Report 2022

August 31, 2022

ATH434 Phase 2 clinical launched in Europe

August 25, 2022

First Patient dosed in ATH434 Phase 2 Clinical Trial

July 6, 2022

Alterity receives a $4.1 million R&D Tax Refund

June 30, 2022

Regulatory Approval to Proceed with Phase 2 Trial in Italy

June 22, 2022

Alterity Launches ATH434 Phase 2 Clinical Trial

June 2, 2022

UK Regulatory Authorisation to Proceed with Phase 2 Trial

April 27, 2022

New publication shows ATH434 rescues neurons in MSA model

January 28, 2022

Response to ASX Query

January 12, 2022

New US Patent for Compounds to Treat Neurodegeneration

January 5, 2022

First Regulatory Authorization to Proceed with Phase 2 Trial

December 13, 2021

ATH Annual General Meeting Presentation

November 11, 2021

Chairmans Address 2021 Annual General Meeting

November 11, 2021

New Data Advance ATH434 as Neurodegeneration treatment

November 4, 2021

Expanded ATH434 Phase 2 Clinical Development Program

October 18, 2021

← Newer news releases · Older news releases →

Decks

The 5 newest of 47 decks. Every deck is listed under its year.